Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma
Condition: Mesothelioma Interventions: Drug: Nivolumab Injection; Drug: Ipilimumab Injection Sponsors: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Bristol-Myers Squibb Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials